Open an account

DiaMedica Therapeutics

DMAC · NASDAQ

$8.67+$0.80 (+10.17%)TodayMarket closed ·
Prev close $7.87

About DMAC

DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. The company is headquartered in Minneapolis, Minnesota and currently employs 35 full-time employees. The company went IPO on 2008-01-04. The Company’s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of pre-eclampsia, acute ischemic stroke and other vascular diseases. DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) in clinical development for preeclampsia and acute ischemic stroke. KLK1 is a serine protease enzyme that is involved in the regulation of diverse physiological processes via a molecular mechanism that increases the production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factors. In the treatment of preeclampsia, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta.

Employees
35
Headquarters
Minneapolis, Minnesota
Listed
Jan 4, 2008
Sector
Health Care
Industry
Biotechnology
Website
diamedica.com

DMAC key statistics

Market cap
467.54M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
241.04K
Volume
168.18K
Open price
$7.88
High today
$8.87
Low today
$7.88
52 Week high
$10.42
52 Week low
$5.25

DiaMedica Therapeutics (DMAC) at a glance

DiaMedica Therapeutics (DMAC) last traded at $8.67, with a market cap of 467.54M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $7.88 and $8.87. The current price is 10.0% above the day's low and 2.3% below its high.

Volume so far is 168.18K shares, below the average of 241.04K shares a day.

Over the past year DiaMedica Therapeutics has ranged from $5.25 to $10.42, and now sits 66% of the way up that range.

DiaMedica Therapeutics met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.19 per share against an estimate of -$0.204.

The average analyst price target is $17.34, 100.0% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 2 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 5 analystsAvg $17.34
Low
$12.12
Now
$8.67
High
$26.25

DMAC earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 5.7% on average.

  1. Q3 FY24: reported -$0.15 per share against an estimate of -$0.1581
  2. Q4 FY24: reported -$0.18 per share against an estimate of -$0.176
  3. Q1 FY25: reported -$0.18 per share against an estimate of -$0.1836
  4. Q2 FY25: reported -$0.18 per share against an estimate of -$0.1938
  5. Q3 FY25: reported -$0.17 per share against an estimate of -$0.1632
  6. Q4 FY25: reported -$0.17 per share against an estimate of -$0.1836
  7. Q1 FY26: reported -$0.19 per share against an estimate of -$0.1887
  8. Q2 FY26: reported -$0.19 per share against an estimate of -$0.204

DMAC news

  • Press releaseBusiness Wire

    DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar

  • Press releaseBusiness Wire

    DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR Results

  • Press releaseBusiness Wire

    DiaMedica Therapeutics to Participate in Upcoming September Investor Conferences

  • Press releaseBusiness Wire

    DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights

  • Press releaseBusiness Wire

    DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026

  • Press releaseBusiness Wire

    DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Press releaseBusiness Wire

    DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction

  • Press releaseBusiness Wire

    DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program

Similar companies

Companies in the same industry as DiaMedica Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.